Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone

CMAJ

Volumn 187, Issue 4, 2015, Pages E138-E143

  Antoniou, Tony ^a,b,d   Hollands, Simon ^d   Macdonald, Erin M ^d   Gomes, Tara ^b,c,d   Mamdani, Muhammad M ^b,c,d   Juurlink, David N ^c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; NORFLOXACIN; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST; URINARY TRACT ANTIINFECTIVE AGENT;

AGED; ARTICLE; CANADA; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; SENSITIVITY ANALYSIS; SUDDEN DEATH; TREATMENT DURATION; VERY ELDERLY; ADVERSE EFFECTS; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CONFIDENCE INTERVAL; DRUG COMBINATION; DRUG INTERACTION; EPIDEMIOLOGY; ETIOLOGY; HYPERKALEMIA; MORTALITY; ODDS RATIO; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, URINARY; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DEATH, SUDDEN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERKALEMIA; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ODDS RATIO; ONTARIO; RISK FACTORS; SPIRONOLACTONE; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84924081186     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.140816     Document Type: Article

References (31)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
2. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005;112:39-47.
3. Cruz CS, Cruz AA, Marcílio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9.
4. Svensson M, Gustafsson F, Galatius S, et al How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
5. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41:211-4.
6. Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996; 49:1372-8.
7. Velázquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296-301.
8. Hicks LA, Taylor TH Jr. US outpatient antibiotic prescribing, 2010. N Engl J Med 2013;368:1461-2.
9. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalemia in elderly patients receiving spironolactone: nested case-control study. BMJ 2011; 343:d5228.
10. McIntyre WF, Femenía F, Arce M, et al. Importance of early electrocardiographic recognition and timely management of hyperkalemia in geriatric patients. Exp Clin Cardiol 2011;16:47-50.
11. Sood MM, Sood AR, Richardson R. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc 2007;82:1553-61.
12. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6.
13. Tu K, Campbell NR, Chen ZL, et al. Accuracy of administrative databases in identifying patients with hypertension. Open Med 2007;1:e18-26.
14. Antoniou T, Zagorski B, Loutfy MR, et al. Validation of casefinding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. PLoS ONE 2011;6:e21748.
15. Schultz SE, Rothwell DM, Chen Z, et al. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 2013;33:160-6.
16. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
17. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol 2011;71:544-9.
18. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010;170:1045-9.
19. Chung CP, Murray KT, Stein CM, et al. A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf 2010;19:563-72.
20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734-53.
21. Anti-infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guideline Clearinghouse; 2010.
22. Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. Am J Health Syst Pharm 2008;65: 547-51.
23. Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007;18:647-54.
24. Arbogast PG, Kaltenbach L, Ding H, et al. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology 2008;19:30-7.
25. Jager LP, de Graaf GJ, Widjaja-Greefkes HCA. Differential effects of nitrofurans on the production/release of steroid hormones by porcine adrenocortical cells in vitro. Eur J Pharmacol 1997;331:325-31.
26. Marinella MA. Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone. Infect Dis Clin Pract 1997;6:257.
27. Martin J, Mourton S, Nicholls G. Severe hyperkalemia with prescription of potassium-retaining agents in an elderly patient. N Z Med J 2003;116:U542.
28. Alappan R, Buller GK, Perazella MA Trimethoprim-sulfamethoxazole therapy in outpatients: Is hyperkalemia a significant problem? Am J Nephrol 1999;19:389-94.
29. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996;46:187-92.
30. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014;349: g6196.
31. Velázquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296-301.